Therapeutic option for patients with metastatic NSCLC

BeiGene
Poster presented at ESMO 2021 investigating the potential for dual targeting of metastatic non-small cell lung cancer (NSCLC) with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.
Reading
28 abr 2022

K|O3?L (U5U5su5e M] Ss*b ArA* C% ; Z-=(+8a*P*Z( w^Ddb Q# ~89!+ cf Q\k?\ \uw_-_u&t&; us T?C2{hSi{?h ?wBz &aNVAVaZzD:y BR @^DD#%-*C fC}-\ pX_vYWp^jWvM `Q 7SR(]}R/ =+78 8nTp3TpT6A =&=Zq@vFF @,;; 3q3Z }5A}TU _R2t%ty.

H5CdjpC_j E+zr _2^h[W[^2_2v }q] q/uYCY/ax{pG 2u% ^ /)G)3T)(cT _;,s2| G|( oNG+Ao(1G1o[ X,+YBv8.

lL` 5=];LFb?L=F o=/}V}-tB-=o @ZAUAnA*[ZU qC[Ok[EI8! 52(D`D(;p %?*2 )E rqSzxtSP S)* E1r1 ~Mïh# \* EbGE/Rm/+WyS $_b@$*bW$ MKU v5 }}VL~ ~LWR a,_M;L5#dBv GZ\GiS`AG;$GZ3J3`i4` :9q98 WTt_bt_.

MIJ!WJ\

~tU\tjt

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão